Targeting molecular pathophysiology of type II diabetes: preclinical development and safety evaluation of allosteric MAP Kinase modulators to decrease insulin resistance (GLYKONTROL)

Datum objave: 01.06.2011

Kategorija: Aktualno na Univerzi

Allinky Biopharma

Contact Person

VEGA, MIguel (Mr.)
Allinky Biopharma

Contact
Telephone:              +34-620-947503        +34-620-947503

Collaboration

Project Proposal


Title: Targeting molecular pathophysiology of type II diabetes: preclinical development and safety evaluation of allosteric MAP Kinase modulators to decrease insulin resistance (GLYKONTROL)

Type Details: HEALTH.2012.2.4.3-1
Targeting molecular pathophysiology of type II diabetes: preclinical development and safety evaluation of allosteric MAP Kinase modulators to decrease insulin resistance (GLYKONTROL)


Programme (Collaboration EU R&D): FP7-HEALTH


Expiry Date: 2012-05-26


Target Partner


Organisation Details

Allinky Biopharma

Name: Allinky Biopharma

Region: COMUNIDAD DE MADRID

SPAIN


Type: SME (Small or Medium sized Enterprise)

Number of Employees: < 10



RCN: 87122

Quality Validation Date: 2011-05-26

Update Date: 2011-05-27